Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Non-Standardized Plant Allergenic Extract [EPC]
Robinia Pseudoacacia Bark is a botanical substance utilized primarily as a non-standardized plant allergenic extract. It is categorized under several pharmacological classes, including acidifying agents and calcium chelators, used in specialized diagnostic and therapeutic contexts.
Name
Robinia Pseudoacacia Bark
Raw Name
ROBINIA PSEUDOACACIA BARK
Category
Non-Standardized Plant Allergenic Extract [EPC]
Drug Count
16
Variant Count
30
Last Verified
February 17, 2026
About Robinia Pseudoacacia Bark
Robinia Pseudoacacia Bark is a botanical substance utilized primarily as a non-standardized plant allergenic extract. It is categorized under several pharmacological classes, including acidifying agents and calcium chelators, used in specialized diagnostic and therapeutic contexts.
Detailed information about Robinia Pseudoacacia Bark
References used for this content
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Robinia Pseudoacacia Bark.
Robinia Pseudoacacia Bark, derived from the Black Locust tree native to North America, is a complex botanical substance utilized in modern clinical medicine primarily as a Non-Standardized Plant Allergenic Extract [EPC]. Within the regulatory framework of the U.S. Food and Drug Administration (FDA), this substance is categorized among a diverse group of allergenic products used for the diagnosis and treatment of type I hypersensitivity reactions (allergic reactions mediated by IgE antibodies). Beyond its role as an allergen, Robinia Pseudoacacia Bark is recognized for its unique biochemical properties, including its classification as an Acidifying Activity [MoA] agent and a Calcium Chelating Activity [MoA] agent.
In a clinical context, Robinia Pseudoacacia Bark belongs to a class of drugs called allergenic extracts. These extracts are prepared from the proteins, carbohydrates, and other organic molecules found within the bark of the Robinia pseudoacacia tree. Unlike 'standardized' extracts, which have a known potency measured by a specific bioassay, Robinia Pseudoacacia Bark is 'non-standardized,' meaning its potency is determined by the weight/volume ratio of the raw material to the extracting fluid. This requires healthcare providers to exercise extreme caution and clinical judgment during administration. The FDA has a long history of regulating these extracts under the Public Health Service Act, ensuring that while they are non-standardized, they meet rigorous purity and safety standards for patient use.
The mechanism of action for Robinia Pseudoacacia Bark is multifaceted, depending on its clinical application. When used as an allergenic extract for immunotherapy (allergy shots), it works through 'hyposensitization.' This process involves the gradual administration of increasing amounts of the allergen to the patient. At the molecular level, this shifts the immune response from a Th2-dominated profile (which produces IgE and triggers allergy symptoms) to a Th1-dominated profile. It also induces the production of 'blocking antibodies' (IgG4), which compete with IgE for binding sites on the allergen, thereby preventing the release of histamine and other inflammatory mediators from mast cells and basophils.
Furthermore, the bark contains specific toxalbumins, most notably 'robin' and 'phasin.' These proteins act as lectins, which can bind to specific carbohydrate moieties on cell surfaces. In its role as an Acidifying Activity [MoA] agent, certain constituents within the bark are thought to influence the pH of gastric or systemic environments, a property sometimes explored in integrative or homeopathic contexts for the management of hyperacidity (excessive stomach acid). As a Calcium Chelating Activity [MoA] agent, the bark contains organic compounds that can form stable complexes with calcium ions. This chelation can interfere with calcium-dependent enzymatic processes or the structural integrity of certain biological membranes, though this specific MoA is typically utilized in highly specialized diagnostic or chemical settings rather than standard systemic therapy.
Robinia Pseudoacacia Bark is primarily indicated for:
Robinia Pseudoacacia Bark is typically available in the following forms:
> Important: Only your healthcare provider can determine if Robinia Pseudoacacia Bark is right for your specific condition. Because it is a non-standardized extract, the transition between different manufacturers or even different lots of the same manufacturer requires medical supervision and often a dose reduction to ensure safety.
For allergen immunotherapy, the dosage of Robinia Pseudoacacia Bark is highly individualized. There is no 'standard' dose because the extract is non-standardized. Treatment typically follows two phases:
For diagnostic skin testing, a single drop of the extract is applied to the skin (prick test), or a minute amount (0.02 mL) is injected intradermally. Results are read after 15-20 minutes based on the size of the wheal and flare reaction.
Robinia Pseudoacacia Bark extracts may be used in children, but the 'starting dose' is often even more conservative than in adults. Clinical studies suggest that children as young as 5 years old can safely undergo immunotherapy, provided they can communicate symptoms of an impending systemic reaction. Dosing is based on clinical sensitivity rather than weight-based formulas. It is not generally recommended for children under 5 due to the difficulty of monitoring for early signs of anaphylaxis.
No specific dosage adjustments are provided by the manufacturers for renal impairment, as the systemic absorption of the proteins is minimal. However, patients with compromised renal function should be monitored for fluid balance if receiving large volumes of parenteral fluids.
No adjustments are typically required for hepatic impairment, as the metabolism of the extract does not rely on liver enzymes like the CYP450 system.
Elderly patients (over 65) should be evaluated for cardiovascular stability before beginning therapy. If an elderly patient is taking beta-blockers for hypertension or heart disease, the use of Robinia Pseudoacacia Bark may be contraindicated or require extreme caution due to the increased difficulty of treating anaphylaxis in these patients.
Robinia Pseudoacacia Bark extracts for immunotherapy must NEVER be self-administered. They must be given by a healthcare professional in a clinical setting equipped to treat anaphylaxis.
If a dose in the build-up phase is missed, the next dose may need to be reduced.
An overdose of Robinia Pseudoacacia Bark extract usually manifests as a severe systemic allergic reaction (anaphylaxis).
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance. The 'non-standardized' nature of this drug means that small changes in volume can lead to large changes in biological effect.
Most patients receiving Robinia Pseudoacacia Bark extracts will experience local reactions at the site of injection. These are generally considered a normal part of the immune system's response to the therapy.
> Warning: Stop taking Robinia Pseudoacacia Bark and call your doctor immediately if you experience any of these symptoms, which may indicate a life-threatening systemic reaction.
When used correctly for immunotherapy, Robinia Pseudoacacia Bark is generally not associated with long-term organ toxicity. However, the primary long-term 'effect' is a permanent change in the immune system's sensitivity. In rare cases, prolonged use of allergenic extracts has been studied for potential links to autoimmune phenomena, though no definitive causal relationship has been established in large-scale clinical trials.
While Robinia Pseudoacacia Bark may not always carry a specific 'Black Box' on every individual vial, the FDA requires a general class warning for all allergenic extracts regarding the risk of severe non-standardized reactions.
Report any unusual symptoms to your healthcare provider. Even a 'large' local reaction can be a predictor of a future systemic reaction, so communication with your clinical team is vital.
Robinia Pseudoacacia Bark is a potent biological substance. It is not a 'natural supplement' in the sense of over-the-counter herbs; it is a clinical-grade allergenic extract regulated as a drug. The most critical safety information involves the risk of anaphylaxis. Patients must be willing and able to adhere to the strict observation period (30 minutes) following every single injection. If you are unable to stay for observation, you cannot receive this treatment.
No specific individual FDA black box warning exists for Robinia Pseudoacacia Bark specifically, but it falls under the mandatory class warnings for Allergenic Extracts. These warnings emphasize that systemic reactions are unpredictable and can occur even in patients who have previously tolerated the same dose. The warning also states that patients with high levels of sensitivity or those receiving 'rush' immunotherapy protocols are at increased risk.
Robinia Pseudoacacia Bark does not typically cause sedation. However, if a patient experiences a systemic reaction or receives epinephrine, they should not drive or operate machinery until they have been cleared by a medical professional and are fully recovered from the event.
There is no direct chemical interaction between Robinia Pseudoacacia Bark and alcohol. However, alcohol consumption can cause vasodilation (widening of blood vessels), which may theoretically increase the rate of absorption of the extract and potentially increase the risk or severity of an allergic reaction. It is generally advised to avoid alcohol for several hours before and after an injection.
If therapy is discontinued, there is no 'withdrawal syndrome.' However, the protective effects of the immunotherapy will gradually wane over months or years. If a patient stops therapy for a long period and wishes to restart, they must begin the build-up phase from the lowest concentration again to avoid anaphylaxis.
> Important: Discuss all your medical conditions with your healthcare provider before starting Robinia Pseudoacacia Bark. Ensure your provider knows if you are taking any medications for blood pressure or heart rhythm.
For each major interaction, the mechanism is usually pharmacodynamic (affecting how the body responds to the drug or its emergency treatments) rather than pharmacokinetic (affecting drug levels). The clinical consequence is almost always an increased risk of an untreatable or severe allergic reaction. The management strategy is typically to switch the patient to alternative medications for their other conditions (e.g., switching from a beta-blocker to a calcium channel blocker) before starting immunotherapy.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. Even 'natural' products can change how your immune system responds to this treatment.
Robinia Pseudoacacia Bark must NEVER be used in the following circumstances:
Conditions requiring careful risk-benefit analysis include:
Patients who are allergic to other members of the Fabaceae family (such as Alfalfa, Clover, or even Soy) may exhibit cross-sensitivity to Robinia Pseudoacacia Bark. This means they are more likely to have a reaction to the extract even if they have never been exposed to Black Locust trees before. Healthcare providers should perform a thorough 'family-tree' allergy assessment before administration.
> Important: Your healthcare provider will evaluate your complete medical history before prescribing Robinia Pseudoacacia Bark. Be honest about your history of asthma and all medications you are currently taking.
Robinia Pseudoacacia Bark is classified as FDA Pregnancy Category C. This means that animal reproduction studies have not been conducted, and there are no adequate and well-controlled studies in pregnant women.
It is not known whether the allergenic proteins in Robinia Pseudoacacia Bark are excreted in human milk. However, because these are large proteins that are broken down in the mother's lymphatic system and are not typically present in high concentrations in the blood, the risk to a nursing infant is considered extremely low. The decision to continue immunotherapy while breastfeeding should be a shared decision between the patient and her doctor.
Robinia Pseudoacacia Bark is used in the pediatric population, primarily for children aged 5 and older.
In patients over 65, the use of Robinia Pseudoacacia Bark requires additional screening.
There is no specific data regarding the use of Robinia Pseudoacacia Bark in patients with kidney failure. However, since the proteins are metabolized locally and systemically by proteases, renal clearance is not the primary route of elimination for the active components. No dose adjustment is usually required, though clinical monitoring is always advised.
Liver disease does not typically affect the safety or efficacy of Robinia Pseudoacacia Bark, as the extract does not undergo significant hepatic metabolism via the cytochrome P450 system. Patients with severe hepatic failure should be monitored for general immune competence.
> Important: Special populations require individualized medical assessment. Always inform your allergist if you are pregnant, planning to become pregnant, or are treating an elderly family member.
Robinia Pseudoacacia Bark acts as a complex biological modifier. Its primary clinical mechanism is Immunological Desensitization. The extract contains various proteins (antigens) that, when introduced sub-dermally, are taken up by antigen-presenting cells (APCs) such as dendritic cells. These cells present the allergen to T-lymphocytes. In an allergic individual, this normally triggers a Th2 response. Repeated, low-dose exposure via the extract induces 'T-cell anergy' or the development of Regulatory T-cells (Tregs) that secrete IL-10 and TGF-beta. These cytokines suppress the allergic inflammation and signal B-cells to switch production from IgE to IgG4.
Additionally, the bark's Acidifying Activity is attributed to its content of organic acids (like syringic and protocatechuic acid), while its Calcium Chelating Activity is linked to specific flavonoids and tannins that possess high affinity for divalent cations. These secondary mechanisms are more relevant in the bark's chemical interactions and specialized diagnostic applications than in its role as a respiratory allergen.
| Parameter | Value |
|---|---|
| Bioavailability | Low (systemic), High (local lymphatic) |
| Protein Binding | N/A (is a protein itself) |
| Half-life | Variable (days for protein fragments) |
| Tmax | 1-2 hours (for peak systemic absorption) |
| Metabolism | Proteolysis (Protease enzymes) |
| Excretion | Renal (as metabolites) |
Robinia Pseudoacacia Bark is classified as a Non-Standardized Plant Allergenic Extract. It shares this class with other tree extracts like Oak, Hickory, and Elm. It is distinct from 'Standardized' extracts like Short Ragweed or Cat Hair, which have federally mandated potency units (BAU/mL).
Medications containing this ingredient
Common questions about Robinia Pseudoacacia Bark
Robinia Pseudoacacia Bark is primarily used as an allergenic extract for the diagnosis and treatment of allergies to the Black Locust tree. In clinical settings, it is used in skin prick tests to confirm if a patient is allergic to this specific plant. If an allergy is confirmed, the extract is used in immunotherapy, commonly known as 'allergy shots,' to help desensitize the patient's immune system over time. This treatment aims to reduce symptoms of allergic rhinitis and asthma. Additionally, it has specialized uses as an acidifying and calcium-chelating agent in certain clinical diagnostic reagents.
The most common side effects are localized reactions at the site of the injection, occurring in more than 90% of patients at some point during therapy. These include redness, swelling, and itching where the needle entered the skin. These reactions are usually mild and disappear within 24 hours. Some patients may also experience a temporary increase in their usual allergy symptoms, such as sneezing or itchy eyes. While rare, systemic reactions like hives or 'feeling tired' can occur. Your doctor will monitor you closely after each dose to manage these effects.
It is generally recommended to avoid alcohol for several hours before and after receiving an injection of Robinia Pseudoacacia Bark. While there is no direct chemical interaction between the extract and alcohol, alcohol causes blood vessels to dilate (expand). This vasodilation can increase the speed at which the allergen is absorbed into your bloodstream, potentially increasing the risk of a systemic allergic reaction or making a reaction more severe. Furthermore, alcohol can mask the early symptoms of anaphylaxis, making it harder for you or your doctor to recognize an emergency. Always follow your allergist's specific instructions regarding lifestyle choices during treatment.
Robinia Pseudoacacia Bark is classified as Pregnancy Category C, meaning its safety has not been fully established through rigorous clinical trials in pregnant women. The main concern during pregnancy is not the drug itself, but the risk of a severe allergic reaction (anaphylaxis) in the mother. Anaphylaxis can lead to a dangerous drop in blood pressure and oxygen, which can harm the developing fetus. Most allergists will not start a new course of Robinia Pseudoacacia Bark during pregnancy. However, if you are already on a stable maintenance dose and are tolerating it well, your doctor may decide to continue the treatment while monitoring you very closely.
The timeframe for Robinia Pseudoacacia Bark to provide relief depends on the use case. For diagnostic skin testing, the results are almost immediate, appearing within 15 to 20 minutes. However, for therapeutic immunotherapy, the process is much slower. Most patients do not notice a significant reduction in their allergy symptoms until they reach their maintenance dose, which typically takes 3 to 6 months of weekly injections. Full clinical benefit is often not realized until the patient has been on maintenance therapy for 12 months or longer. Consistency is key to the success of this treatment.
Yes, you can stop taking Robinia Pseudoacacia Bark injections suddenly without experiencing physical withdrawal symptoms like those seen with narcotics or antidepressants. However, stopping the treatment prematurely will result in the return of your allergy symptoms over time, as your immune system has not been fully desensitized. If you stop for several weeks and then decide to restart, you cannot simply take your last dose; you must restart at a much lower concentration to avoid a severe allergic reaction. Always discuss your plans to stop or pause therapy with your allergist to ensure a safe transition.
If you miss a dose of Robinia Pseudoacacia Bark, you should contact your allergist's office immediately to reschedule. The safety of the next dose depends on how long it has been since your last injection. If you only miss a few days, you may be able to continue with your scheduled dose increase. However, if you miss one or more weeks, your doctor will likely need to repeat your last dose or even reduce the dose to ensure your safety. Never attempt to 'double up' on doses to make up for a missed one, as this significantly increases the risk of anaphylaxis.
There is no clinical evidence to suggest that Robinia Pseudoacacia Bark causes weight gain. The extract consists of proteins and organic compounds administered in very small quantities (usually less than 0.5 mL) via injection. It does not contain hormones, steroids, or calories in an amount that could affect body weight. If you experience weight gain while undergoing immunotherapy, it is likely due to other factors, such as other medications (like oral steroids sometimes used for asthma) or changes in lifestyle. You should discuss any unexpected weight changes with your primary care physician.
Robinia Pseudoacacia Bark can be taken with many medications, but there are critical exceptions. You must inform your doctor if you are taking beta-blockers, MAO inhibitors, or tricyclic antidepressants, as these can make an allergic reaction much more dangerous and difficult to treat. Most standard allergy medications, like antihistamines or nasal steroids, are fine to take during treatment and may actually help manage local side effects. However, you must stop taking antihistamines several days before any skin testing, as they will block the test results. Always provide your allergist with a complete list of your current medications.
The concept of 'generic' is slightly different for allergenic extracts like Robinia Pseudoacacia Bark. Because these are non-standardized biological products, extracts from different manufacturers are not considered 'bioequivalent' in the same way generic aspirin is to brand-name aspirin. While several different biological laboratories may produce Black Locust Bark extract, they are not interchangeable. If your doctor switches you from one manufacturer's extract to another, they will typically reduce your dose and gradually build it back up to ensure that the new product does not cause an unexpected reaction.